Phase 1, Two-Part, Multicenter, Non-Randomized, Open-Label, Multiple Dose First-In-Human Study Of Ds-8201A, In Patients With Advanced Solid Malignant
Posted Date: May 15, 2019
- Investigator: Trisha Wise-Draper
- Type of Study: Drug
The main purpose of this study is to Test the safety of a study drug called DS-8201a and see what effects (good and bad) it has on you and your cancer. DS-8201a targets a protein called human epidermal growth factor receptor 2 (HER2) which is found on the surface of cancer cells in large amounts. DS
Criteria:
To Be Eligible To Participate In This Study, Patients Must Have Her2 Positive Breast Cancer, Her2 Po
Keywords:
Breast, Cancer, Ds8201-A-J101, Gastrointestinal, Phase I
For More Information:
Billie Boaz
(513) 584-7698
kastla@ucmail.uc.edu